Tafasitamab
Tafasitamab is a humanized anti-CD19 monoclonal antibody with enhanced Fc-region modifications that increase binding affinity to Fc-gamma receptors and complement proteins, augmenting antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against CD19-positive B-cell malignancies. It is approved in combination with lenalidomide for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and is under investigation for other B-cell lymphomas and solid tumors. CD19 expression across B-cell development makes it a broadly applicable target in B-cell lymphomas.
Terapötik Alanlar
Etki Mekanizması
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Tafasitamab is a humanized anti-CD19 monoclonal antibody with enhanced Fc-region modifications that increase binding affinity to Fc-gamma receptors and complement proteins, augmenting antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against CD19-positive B-cell malignancies. It is approved in combination with lenalidomide for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and is under investigation for other B-cell lymphomas and solid tumors. CD19 expression across B-cell development makes it a broadly applicable target in B-cell lymphomas.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Tafasitamab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4298047. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tafasitamab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tafasitamab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tafasitamab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tafasitamab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tafasitamab"></drugfyi-drug>